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Abstract: Normalization of blood glucose is essential for the prevention of diabetes mellitus 
(DM)-related microvascular and macrovascular complications. Despite substantial literature to 
support the beneﬁ  ts of glucose lowering and clear treatment targets, glycemic control remains 
suboptimal for most people with DM in the United States. Pharmacokinetic limitations of 
conventional insulins have been a barrier to achieving treatment targets secondary to adverse 
effects such as hypoglycemia and weight gain. Recombinant DNA technology has allowed 
modiﬁ  cation of the insulin molecule to produce insulin analogues that overcome these phar-
macokinetic limitations. With time action proﬁ  les that more closely mimic physiologic insulin 
secretion, rapid acting insulin analogues (RAAs) reduce post-prandial glucose excursions and 
hypoglycemia when compared to regular human insulin (RHI). Insulin glulisine (Apidra®) is a 
rapid-acting insulin analogue created by substituting lysine for asparagine at position B3 and 
glutamic acid for lysine at position B29 on the B chain of human insulin. The quick absorption 
of insulin glulisine more closely reproduces physiologic ﬁ  rst-phase insulin secretion and its 
rapid acting proﬁ  le is maintained across patient subtypes. Clinical trials have demonstrated 
comparable or greater efﬁ  cacy of insulin glulisine versus insulin lispro or RHI, respectively. 
Efﬁ  cacy is maintained even when insulin glulisine is administered post-meal. In addition, 
glulisine appears to have a more rapid time action proﬁ  le compared with insulin lispro across 
various body mass indexes (BMIs). The safety and tolerability proﬁ  le of insulin glulisine is also 
comparable to that of insulin lispro or RHI in type 1 or 2 DM and it has been shown to be as 
safe and effective when used in a continuous subcutaneous insulin infusion (CSII).  In summary, 
insulin glulisine is a safe, effective, and well tolerated rapid-acting insulin analogue across all 
BMIs and a worthy option for prandial glucose control in type 1 or 2 DM. 
Keywords: glycemic control, glycosylated hemoglobin A1c (HbA1c), rapid-acting insulin 
analogues, type 1 diabetes mellitus, type 2 diabetes mellitus, insulin glulisine, body mass 
index (BMI).
Introduction
The prevalence of diabetes mellitus (DM) is increasing at an alarming rate largely 
due to an aging population coupled with high rates of obesity, unhealthy diet, and 
sedentary lifestyle (IDF 2006). An estimated 7% of the United States population, 
or >20.8 million Americans, have type 1 or type 2 DM, representing a 14% increase 
in prevalence over the last 2 years (ADA 2006). Furthermore, >41 million Americans 
have impaired glucose tolerance (IGT) or impaired fasting glucose (IFG), conditions 
classiﬁ  ed as pre-diabetes because they signiﬁ  cantly increase an individual’s risk for the 
development of diabetes; the expected conversion rate to diabetes for such persons is 
7% per year (ADA 2006). Statistics are equally sobering for the European population. 
The current prevalence of 7.8% is expected to increase to 9.1%, roughly 60 million 
Europeans, by the year 2025 (IDF 2006).Vascular Health and Risk Management 2007:3(3) 246
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The impact of DM on society and the persons affected 
is profound. Both type 1 and 2 DM are associated with 
microvascular and macrovascular complications that result 
in considerable morbidity and an estimated 3.2 million deaths 
per year worldwide (World Health Organization 2006). 
Although there has been an overall decrease in mortality 
from coronary artery disease in patients without DM over 
the last 10 years, there has been a paradoxical increase in 
DM-related mortality (Sobel et al 2003). Despite these sta-
tistics, this disease can be well managed with individualized 
intensive treatment regimens. 
Blood glucose lowering is essential for the prevention 
of DM-related microvascular and macrovascular complica-
tions. The Diabetes Control and Complications Trial (DCCT) 
found that intensive insulin therapy to improve glycemic 
control, as measured by glycosylated hemoglobin (A1c), 
signiﬁ  cantly lowered the risk for retinopathy by 47%, for 
nephropathy by 54%, and for neuropathy by 60% in patients 
with type 1 DM followed for an average of 6.5 years (The 
Diabetes Control and Complications Trial Research Group 
1993). Similar ﬁ  ndings with intensive treatment were seen 
with large cohorts of patients with type 2 DM followed in the 
United Kingdom Prospective Diabetes Study (UKPDS) and 
the Kumamoto studies (UKPDS 1998; Shichiri et al 2000). It 
is estimated that for every percentage point A1c is lowered, 
the risk of microvascular complications is decreased by 37% 
and the risk of macrovascular complications is decreased 
14% (Stratton et al 2000). 
More recent data comes from the Epidemiology of Dia-
betes and Interventions and Complications (EDIC) trial, a 
follow-up study of the DCCT that analyzed study participant 
data for up to 18 years (Nathan et al 2005). In addition to 
observing continued reductions in microvascular complica-
tions, researchers found that intensive therapy during the 
DCCT years was associated with a 42% reduction in the risk 
of cardiovascular disease and a 57% reduction in cardiovas-
cular events, including myocardial infarction, stroke, and 
death. Overall, every 10% reduction in A1c (ie, a decrease 
from an A1c of 8.0% to 7.2%) was associated with a 21% 
decrease in cardiovascular disease.
The American Diabetes Association (ADA), the Ameri-
can Association of Clinical Endocrinologists (AACE), and 
the International Diabetes Federation (IDF) recommend 
near-normalization of plasma glucose levels with target 
A1c values of <7.0%, 6.5%, and 6.5%, respectively 
(IDF 1999; AACE 2002; ADA 2006). Although the ADA 
recommends an A1c goal of <7.0% for patients in general, 
the goal for individual patients should be set as close to nor-
mal (<6.0%) as possible without signiﬁ  cant hypoglycemia 
(ADA 2006).  Each organization also provides speciﬁ  c 
goals for fasting plasma glucose (FPG) and postprandial 
glucose (PPG) (see Table 1) (ADA 2006; AACE 2002; 
IDF 1999).
Despite substantial literature to support the beneﬁ  ts of 
glucose lowering, clear treatment targets, and the avail-
ability of effective treatments, the average A1c in the 
United States remains above 9% (Hirsch 2004). For several 
decades, pharmacokinetic limitations of conventional 
insulins made treatment goals difﬁ  cult to achieve for many 
patients. Studies have shown that intensive regimens with 
these older insulins often results in frequent hypoglycemia, 
weight gain, glucose variability, and wide glucose ﬂ  uctua-
tions (Diabetes Control and Complications Trial Research 
Group 1993; UKPDS 1998).  However, the development 
of recombinant DNA technology has allowed modiﬁ  cation 
of the insulin molecule to produce insulin analogues with 
more physiologic time-action proﬁ  les (see Table 2) (Garg 
and Ulrich 2006). This article discusses the beneﬁ  ts of 
intensive insulin regimens designed to mimic physiologi-
cal basal/bolus insulin secretion, with a focus on the new 
rapid-acting insulin analogue, glulisine.
Background
Type 1 DM, which constitutes 5%–10% of the diabetic popu-
lation, occurs when autoimmune destruction of the β-cells 
leads to absolute insulin deﬁ  ciency. Patients with type 1 DM 
are therefore dependent on exogenous insulin replacement 
for survival. Type 2 DM, the more common form of the 
disease, results from a combination of relative insulin deﬁ  -
ciency and a defect in insulin action, or insulin resistance, 
which is frequently associated with obesity. Initially, patients 
Table 1 Treatment goals for glycemia (% of patients to targets)
 ADA  IDF  AACE
A1c(%) <7.0  <6.5  <6.5
FPG(mg/dL) 80–120  <100  <110
2-h PPG(mg/dL)  <180  <135  <140
ADA 2006:   “The A1c goal for the individual patient is an A1c as close to normal 
(<6%) as possible without signiﬁ  cant hypoglycemia”.
Sources: ADA 2006. Standards of medical care in diabetes – 2006. Diabetes Care, 
29(Suppl 1):S4-S42; AACE 2002. American College of Endocrinology. Medical guidelines 
for the management of diabetes mellitus: The AACE system of intensive diabetes 
self-management – 2002 update. Endocr Pract, 8(Suppl 1):40–82; IDF. 1999. A desktop 
guide to type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med, 
16:716–30.
Abbreviations: AACE, American Association of Clinical Endocrinologists; ADA, 
American Diabetes Association; FPG, fasting plasma glucose; IDF, International 
Diabetes Federation; PPG, postprandial glucose.Vascular Health and Risk Management 2007:3(3) 247
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with insulin resistance may have sufﬁ  cient β-cell function 
to compensate for the increased peripheral insulin demand 
(Plonsky et al 1996). However, once β-cell failure begins, 
abnormalities in glycemia occur.
Patients with type 2 DM have a loss of ﬁ  rst phase 
insulin release from pancreatic β-cells, which results in 
PPG excursions (Plonsky et al 1996). Furthermore, as the 
disease progresses, the β-cells lose the ability to maintain 
sufﬁ  cient basal insulin secretion leading to increased FPG 
(Plonsky et al 1996). In type 2 DM, there is an approxi-
mate 50% loss of β-cell function at the time of diagnosis, 
followed by a gradual, yet progressive decline (UKPDS 
1995). Chronic hyperglycemia may further impair β-cell 
function and tissue sensitivity to insulin, resulting in an 
even greater deﬁ  cit in insulin secretion and action (Rossetti 
et al 1990).
Excessive post-prandial glucose excursions may elevate 
A1c levels even when FPG remains in goal range (Monnier 
et al 2003). Although A1c is determined by a combination 
of fasting and PPG levels, the exact contribution of each 
is not known. One study done using intermittent glucose 
monitoring demonstrated that at higher A1c values 
(A1c >8%), FPG had a more signiﬁ  cant inﬂ  uence on overall 
control, however as patients got closer to target A1c, the post-
prandial component became the predominant factor. A more 
recent trial conducted using continuous glucose monitoring 
showed that FPG was normal only for patients with an A1c 
<6% and that PPG continued to inﬂ  uence average glycemic 
control even at higher A1c values (Figure 1) (Garg 2006). 
Regardless of the exact role of FPG vs PPG, it is evident 
that regimens must lower both fasting and post-prandial 
hyperglycemia to achieve therapeutic goals.
Basal/bolus therapy
Intensive insulin therapy for patients with type 1 DM should 
consist of a basal/bolus regimen which can be achieved with 
a combination of long/intermediate and short- or rapid-acting 
insulins or a continuous infusion of a short- or rapid-acting 
insulin via an insulin pump. Unless a patient presents with 
profound hyperglycemia, type 2 DM can and should be 
initially managed with diet and exercise with or without the 
addition of oral glucose-lowering medications. Lifestyle 
modiﬁ  cations centered around diet, exercise, and weight loss 
can have a profound effect on insulin sensitivity and should 
be the ﬁ  rst step in the management of type 2 DM (ADA 
2006). Speciﬁ  cally, overweight patients should be encour-
aged to achieve and maintain a weight loss of at least 7% 
of total body weight through a healthy diet and 150 minutes 
per week of moderate intensity exercise. Furthermore, the 
Diabetes Prevention Program Research Study showed that 
if these interventions are initiated early enough, they can 
prevent or delay the progression of pre-diabetes to diabetes 
(Diabetes Prevention Program Research Group 2002). 
However, because type 2 DM is a progressive disease, 
lifestyle interventions alone are often not sufficient to 
maintain glycemic control over time (Turner et al 1999). 
Most patients will require multiple pharmacological agents 
to achieve glucose targets and eventually, as further β-cell 
deterioration results in failure of the oral agents to control 
hyperglycemia, many patients need insulin introduced 
(Turner et al 1999; UKPDS 1995). 
When utilized in patients with either type 1 or 2 DM, an 
ideal intensive insulin regimen mimics endogenous basal and 
prandial insulin secretion as closely as possible. Basal insulin 
release regulates hepatic glucose homeostasis in the fasting 
Table 2 Pharmacokinetic parameters of available insulins
Insulin preparations  Onset of action  Peak of action (h)  Duration of action (h)
   Rapid-acting
Regular human insulin  30–60 min  2–4  6–8
Lispro/aspart/glulisine 5–15  min  1–2  3–4
  Intermediate-acting
NPH 1–3  h  5–7  13–16
Lente 1–3  h  4–8  13–20
Detemir 3–4  h  4–6  20
  Long-acting
Glargine 1–2  h  No  peak  24
Ultralente 2–4  h  8–14  <20
  Pre-mix
Insulin lispro 75/25  15 min  0.5–1.2  13–16
Insulin aspart 70/30  5–15 min  Dual  10–16
Adapted from Garg SK, Ulrich H. 2006. Achieving goal glycosylated hemoglobin levels in type 2 diabetes mellitus: practical strategies for success with insulin therapy. Insulin, 
1:109–21.Vascular Health and Risk Management 2007:3(3) 248
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state and supplies approximately 50% of an individual’s 
overall insulin requirement (Wittlin et al 2002). The bolus 
component of endogenous insulin secretion consists of 
rapidly released short-lived bursts of insulin in response to 
prandial stimuli. Postprandial insulin is released in a 2- to 
5-minute burst (ﬁ  rst phase) followed by a slow increase in 
insulin release lasting 5–52 minutes (second phase) (Wittlin 
et al 2002). The ﬁ  rst-phase insulin secretion at mealtime 
inhibits endogenous gluconeogenesis in the liver and disposal 
of the carbohydrate load, thereby limiting PPG excursions. 
Early normalization of glucose after a meal is important, 
especially in type 2 DM to prevent late hyperinsulinemia and 
prolonged stress on β-cells (Rossetti et al 1990). 
Conventional insulin vs rapid acting 
analogues
Regular human insulin (RHI) was the only short-acting 
bolus insulin available for many years. Because it requires 
the addition of zinc for stability, RHI exists as a molecular 
hexamer that, once injected, must break down into dimers 
and ultimately monomers to be absorbed and biologically 
active (Wittlin et al 2002). Although RHI has advantages over 
previously used pork and bovine insulins, its slower onset and 
longer duration of action do not completely mimic endog-
enous insulin secretion after a carbohydrate load (Wittlin et al 
2002). Patients should take injections 30–45 minutes prior 
to a meal to prevent extended postprandial hyperglycemia 
and subsequent hypoglycemia during its longer duration of 
action. However, most patients do not follow this recommen-
dation (Overmann and Heinemann 1999). Furthermore, peak 
concentrations may not occur until 2–4 hours after injection, 
requiring frequent snacks to avoid hypoglycemia and thereby 
increasing the potential for weight gain. 
The advent of recombinant DNA technology using a 
non-pathogenic strain of Escherichia coli (K12) has facili-
tated the development of insulin analogues that overcome 
the pharmacokinetic limitations of RHI. Amino acid sub-
stitutions in the insulin molecule allows weak dimeric and 
hexamer formation and thereby rapid disassociation of the 
dimers and hexamers after subcutaneous injection, resulting 
Figure 1 Fasting glucose (12 fasting glucose (12–7 am) vs A1c. Reproduced with permission from Garg S. 2006. Safety, accuracy, and improvement in glucose proﬁ  les 
observed using a 7-day continuous glucose sensor. Diabetes Care®, 29:2644-9. Copyright © 2006 American Diabetes Association.
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in rapid absorption and onset of action (Howey et al 1994). 
Currently available rapid acting analogues (RAAs), which 
include insulin lispro, insulin aspart, and insulin glulisine, 
demonstrate less variability in absorption at the injection 
site and potentially less variability in and among patients 
(Howey et al 1994). RAAs have shown greater efﬁ  cacy in 
reducing post-prandial glucose excursions and hypoglycemia 
when compared with RHI (Anderson et al 1997; Home et al 
1998; Garg et al 1999). A meta-analysis of comparative tri-
als with insulin lispro and RHI reported a 25% reduction in 
the frequency of severe hypoglycemia (Brunelle et al 1998). 
Some, but not all trials have shown modest reductions in A1c 
with these analogues. One meta-analysis noted a small but 
signiﬁ  cant decrease of –0.12% in A1c with RAAs vs RHI in 
patients with type 1 DM; however, this beneﬁ  t was not seen 
with the type 2 DM population (Plank et al 2005).
Insulin glulisine
Insulin glulisine (Apidra®) is a rapid-acting insulin analogue 
created by making two amino acid substitutions in the B chain 
of human insulin: lysine for asparagine at position B3 and 
glutamic acid for lysine at position B29 (see Figure 2) (Garg 
et al 2005). As with other RAAs these modiﬁ  cations to the 
insulin molecule reduce its tendency to aggregate as hexam-
ers, allowing rapid dissociation and absorption following 
a subcutaneous injection. The quick absorption of insulin 
glulisine more closely reproduces physiologic ﬁ  rst-phase 
insulin secretion.
Insulin glulisine is approved in the United States and 
Europe for the treatment of type 1 and type 2 DM in adults. 
It may be administered via subcutaneous injection (abdomen, 
thigh, or deltoid) or CSII. When utilized as a prandial sub-
cutaneous injection, it should be given 15 minutes pre-meal 
or within 20 minutes post-meal.
Pharmacodynamics/
pharmacokinetics
Insulin glulisine demonstrates equivalent bioefﬁ  cacy with RHI. 
In an initial randomized, open-label crossover study with 16 
healthy volunteers (mean age = 22 years, mean body mass index 
[BMI] = 23.9 kg/m2) the euglycemic clamp technique was used 
to compare the molar efﬁ  cacy of the two insulins (Becker et al 
2005). During a 2-hour continuous infusion, insulin glulisine and 
RHI had superimposible mean glucose infusion rates (GIR) and 
area under the glucose infusion rate time-curves at steady state 
(GIR-AUCSS). Both insulins also presented equal total glucose 
exposure as measured by the glucose infusion rate time-curve 
from time 0 to clamp end (GIR-AUC0-clamp end). The overall 
equivalent bioefﬁ  cacy demonstrated that patients can switch 
from RHI to insulin glulisine on a unit-per-unit basis. A random-
Figure 2 Glulisine vs RHI vs lispro: pharmacokinetics in obese individuals. Reproduced with permission from Garg SK, Ellis SL, Ulrich H. 2005. Insulin glulisine: a new rapid-
acting insulin analogue for the treatment of diabetes. Expert Opin Pharmacother, 6:643–51. Copyright © 2005 Informa Healthcare. 
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ized, double-blind study also employing the euglycemic clamp 
technique in healthy volunteers was initiated to compare plasma 
concentrations and time action proﬁ  les of insulin glulisine, insulin 
lispro, and RHI (Becker et al 2003). Median time to maximum 
plasma concentration (tmax) and mean residence time (MRT) for 
insulin glulisine and insulin lispro were approximately half that 
of RHI (see Figure 3) (Becker et al 2003).
More recently, a larger randomized crossover study was 
conducted by Spitzer et al to evaluate the pharmacokinetics 
and pharmacodynamics of insulin glulisine versus insulin 
lispro in lean to obese individuals (Spitzer et al 2006). Eighty 
healthy subjects were stratiﬁ  ed into one of 4 groups based 
on BMI (<25, 25–<30, 30–<35, and >35 kg/m2) and given 
insulin glulisine and insulin lispro at doses of 0.2 U/kg and 
0.4 U/kg in random order over a 4-day study period with a 
euglycemic glucose clamp. GIR and insulin concentration 
(INS) were measured for 10 hours following the dose. Over-
all, onset of exposure and activity, as measured by INS-t10% 
and GIR-t10%, was 6 minutes faster with insulin glulisine. 
Early insulin exposure and early metabolic action were 
consistently greater by 18%–30% with insulin glulisine than 
insulin lispro, which was signiﬁ  cant in the total population 
and across a wide range of BMIs. 
Insulin glulisine has been shown to maintain its rapid-
acting kinetic proﬁ  le in studies that enrolled patients with 
type 1 or 2 DM. In a randomized crossover study of 20 pa-
tients with type 1 DM, insulin glulisine was absorbed more 
quickly than RHI, although total availability did not differ 
between the insulins (Nosek et al 2004). Patients received 
a 0.15 U/kg subcutaneous injection of either RHI 30 min-
utes pre-meal or insulin glulisine immediately before or 15 
minutes post-meal. Mean AUC from 0 to 2 hours (AUC2) 
was 7278 and 4258 μIU min/ML with insulin glulisine and 
RHI respectively (p < 0.05). However, mean insulin AUC 
from 0 to 6 hours (AUC6) did not differ between groups 
(11,912 vs 11,550 μIU min/mL). Mean Cmax, AUC6, and tmax 
were equivalent between the pre- and post-meal glulisine 
injections, indicating that the analogue is safe and effective 
when administered either before or after a meal. This may 
provide greater ﬂ  exibility for patients, especially those prone 
to forgetting pre-meal injections. 
In a comparison study of patients with type 2 DM, 
AUC2 was again signiﬁ  cantly greater with insulin glulisine 
compared with RHI (7661 vs 4221), but at the end of the 
10 hour clamp, AUC10 was comparable between these two 
insulins (18,408 vs 19,731 μIU min/mL) (Becker et al 2004). 
Figure 3 Glulisine duration of activity shorter than regular human insulin (RHI)F. Reproduced with permission from Becker RHA, Frick A, Wessels D. 2003. 
Pharmacodynamics and pharmacokinetics of a new rapidly-acting insulin analog, insulin glulisine [abstract no. 471-P] Diabetes®, 52(Suppl1):A110. Copyright © 2003 American 
Diabetes Association.
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This study, which also used insulin lispro as a comparator, 
conﬁ  rmed that both of these rapid-acting insulin analogues 
have equivalent pharmacokinetic and pharmacodyamic pro-
ﬁ  les, which more closely mimic physiologic prandial insulin 
secretion compared with RHI. 
The volume of distribution for insulin glulisine fol-
lowing intravenous administration is 13 L (vs 21 L for 
RHI) (Gabry 2004). Half-lives for insulin glulisine and 
RHI were measured at 13 and 17 minutes (intravenous 
administration) and 42 and 86 minutes (subcutaneous 
injection) respectively (Gabry 2004). The pharmacokinet-
ics of insulin glulisine were comparable between various 
sites of subcutaneous injection (Frick et al 2003). Follow-
ing injection into abdominal, deltoid, or femoral sites in 
healthy volunteers, insulin glulisine demonstrated con-
sistent pharmacokinetic parameters, including absolute 
bioavailability. It was noted that the use of the abdominal 
route led to slightly more rapid insulin delivery. 
Special populations 
The rapid-acting pharmacokinetic properties of insulin glu-
lisine have been consistent among various patient subtypes 
including: obesity, renal impairment, different ethnicity, 
and childhood. 
The pharmcodynamic and pharmacokinetic properties for 
insulin glulisine were initially compared to RHI and insulin 
lispro in a randomized, double-blind, crossover study in 
obese non-diabetic individuals (n = 18, BMI = 30–40 kg/m2) 
(Frick et al 2004). Patients received single doses of insulin 
(0.3 IU/kg) administered subcutaneously in the abdomen. 
The Cmax for RHI, insulin lispro, and insulin glulisine was 
203, 133, and 77 μIU/mL, respectively.  Tmax (144, 99, and 
76 minutes) and MRT (229, 166, and 149 minutes) were 
shortest with insulin glulisine, and the difference between 
the two analogues was statistically signiﬁ  cant over the ﬁ  rst 
2 hours (Figure 4). Total glucose disposal was equivalent 
for all insulins studied. Of note, there was a correlation 
found between the thickness of the abdominal fat area and 
the time action proﬁ  les for RHI and insulin lispro. This cor-
relation was not found for insulin glulisine, suggesting that 
this analogue may better maintain its rapid-acting kinetics 
over a range of subcutaneous fat thickness. This ﬁ  nding 
was supported by the more recent data from a larger trial 
by Spitzer et al, described previously (Spitzer et al 2006). 
The trial demonstrated advantages of early action of insulin 
glulisine versus insulin lispro in individuals who were lean, 
overweight, obese, or severely obese.
A single dose study was conducted to evaluate insulin 
glulisine in non-diabetic patients (n = 24) with moder-
ate (creatinine clearance = 30–50 mL/min), severe (<30 
mL/min), or no (>80 ml/min) renal impairment (Jaros et 
al 2004). No differences in absorption, as measured by 
Cmax, tmax, and AUC2, were noted between groups. There 
was, however, a correlation between renal impairment 
Figure 4 Fast-acting glulisine: substitutions on endogenous insulin B chain.
A chain
B chain
Gly
1
5
1
5
10
15
20
S
S
20
15 10
Gln
Ile Gln
Cys
Phe
His
His
Leu
S
S
S
S
Phe
25
30 Pro
Lys
Thr
Ala
Modified Human Insulin
Glulisine:
Replacement of asparagine B3 with lysine 
and lysine B29 with glutamic acid
Glu Lys
Substitutions favor
rapid dissociation 
after SC injection
Asn
GlyVascular Health and Risk Management 2007:3(3) 252
Ulrich et al
and total exposure and total clearance, which were in-
creased by 29%–47%. 
Insulin glulisine was compared with RHI and insulin 
lispro in a randomized, double-blind, crossover study that 
enrolled Japanese and Caucasian males matched for BMI 
(Rave et al 2004). Insulin glulisine demonstrated a more 
rapid-acting time proﬁ  le and greater glucose lowering at 2 
hours compared with RHI. Slight, but non-signiﬁ  cant, differ-
ences were noted for onset of activity and metabolic effect of 
all insulins in Japanese versus Caucasian individuals. 
Likewise, the rapid-acting pharmacokinetic proﬁ  le of 
insulin glulisine was maintained in pediatric and adolescent 
patients with type 1 DM (Danne et al 2005). Absorption 
was more rapid (tmax 54 vs 66 minutes) and blood glucose 
excursions were lower with the insulin analogue compared 
to RHI. Overall, the pharmacokinetic properties of insulin 
glulisine in pediatric patients were similar to those seen in 
healthy and diabetic adult patients. 
Efﬁ  cacy and tolerability
Type 1 DM
A multinational, randomized, controlled, open-label parallel 
group study compared insulin glulisine and insulin lispro 
administered subcutaneously 0–15 minutes pre-meal in 
adults with type 1 DM (n = 672) (Dreyer et al 2005). Prior 
to randomization, a 4-week run-in phase was initiated with 
insulin glargine for basal coverage and RHI for bolus insulin. 
Patients were then randomized to one of the two rapid-acting 
analogues for bolus control over a 26-week treatment phase. 
The primary outcome was the change in A1c from baseline 
to endpoint (subject’s last available measurement).
Similar reductions in A1c occurred in both study groups 
at 12 and 26 weeks and at study endpoint (mean change 
from baseline = –0.14% in both groups), demonstrating 
non-inferiority. There was no signiﬁ  cant difference in the 
proportion of patients achieving target A1c. Furthermore, 
self-monitored 7-point blood glucose proﬁ  les were compa-
rable between the insulin glulisine and insulin lispro groups. 
Basal insulin doses increased for the patients taking insulin 
lispro group but not for patients taking insulin glulisine, 
which led to a reduced total daily dose for the insulin glu-
lisine group and an increased total daily dose for insulin 
lispro. Hypoglycemic events (symptomatic, nocturnal, 
and severe) were comparable between treatments and no 
appreciable differences were observed in safety variables: 
systemic hypersensitivity reactions, injection site reactions, 
insulin or Escherichia coli antibody formation, hematology 
or clinical chemistry changes, lipid proﬁ  les, body weight, 
or blood pressure. Similar results were noted in a 26-week 
clinical extension study.
A second large clinical trial compared pre- and post-
meal insulin glulisine injections versus pre-meal RHI 
injections in adult type 1 patients (Garg et al 2005). Again, 
the subjects completed a 4-week run-in period using 
insulin glargine and RHI, then they were subsequently 
randomized to one of the three treatment groups for a 12-
week period. At 8 and 12 weeks, A1c was significantly 
reduced for the pre-meal glulisine subjects compared to 
the post-meal and RHI groups (p < 0.01). There was no 
statistically significant difference in A1c lowering be-
tween insulin post-meal insulin glulisine and RHI. Total 
insulin dose was decreased significantly in both of the 
insulin glulisine groups, secondary to decreases in basal 
insulin requirements. There was a 0.6 kg difference in 
weight at the end of the study between the post-meal 
glulisine subjects and the other groups (–0.3 kg with 
post-meal, +0.3 kg with pre-meal and RHI). Similar rates 
of hypoglycemia and adverse events, including hypersen-
sitivity and injection site reactions, were observed.
Given the proportion of patients with type 1 DM currently 
treated with a continuous subcutaneous insulin infusion 
(CSII), or insulin pump, it is important to assess efﬁ  cacy and 
safety of insulin glulisine for this patient population. This 
was achieved during a multinational, randomized controlled 
12-week trial comparing insulin glulisine with insulin aspart 
used in CSII (Hoogma and Schumicki 2006). There were no 
statistically signiﬁ  cant differences between the two insulins 
with respect to A1c lowering, self-monitored blood glucose 
proﬁ  les, catheter occlusions, mean total insulin dose, and hy-
poglycemia. Seven patients (20.7%) and 14 patients (40.0%) 
reported at least one episode of unexplained hyperglycemia in 
the insulin glulisine and insulin aspart groups, respectively. 
However, this difference was not statistically signiﬁ  cant. 
Four patients (13.8%) in the insulin glulisine group versus 
8 patients (26.7%) in the insulin aspart group experienced at 
least one catheter occlusion. Again, this difference was not 
statistically signiﬁ  cant. The catheter change rate and time 
between catheter changes were comparable between groups. 
Glulisine is a safe an effective option for type 1 patients on 
insulin pump therapy.
Type 2 DM
Insulin glulisine is the ﬁ  rst of the rapid-acting analogues to 
exhibit statistically signiﬁ  cant A1c lowering in comparison 
with RHI in type 2 DM. 876 patients with type 2 DM, under Vascular Health and Risk Management 2007:3(3) 253
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relatively good control (mean baseline A1c = 7.55%) were 
randomized to receive NPH + insulin glulisine or NPH + 
RHI for 26 weeks (Dailey et al 2004). Pre-study oral diabetes 
medications were continued, unless hypoglycemia neces-
sitated a dose reduction. A statistically signiﬁ  cant reduction 
in A1c occurred with insulin glulisine (–0.46% vs –0.30% 
with RHI) at study endpoint. Statistical signiﬁ  cance in 
favor of insulin glulisine was also achieved for differences 
between post-dinner and post-breakfast blood glucose lev-
els. There were no between group differences with respect 
to insulin dose changes, hypoglycemia, weight gain, and 
adverse events. A 26-week extension trial was conducted; 
however the results have not been published. Data on ﬁ  le 
indicate that A1c reductions at the end of the 52 week period 
were –0.23% and –0.13% for insulin glulisine and RHI, 
respectively (Gabry 2004). The signiﬁ  cant reductions in 
self-monitored blood glucose proﬁ  les persisted during this 
extension period.
Safety of insulin glulisine
It is known that amino acid changes of the insulin molecule 
may change binding with the insulin and insulin-like growth 
factor 1 (IGF-1) receptors, thereby potentially increasing 
the risk of mitogenesis, or increased cell growth (Berti et al 
1998). It is therefore necessary to evaluate insulin and IGF-1 
receptor binding for any analogue prior to approval for use. 
A comprehensive preclinical evaluation that compared 
insulin glulisine with RHI concluded that receptor binding 
was similar between the two agents and that insulin glulisine 
did not promote excessive mitogenic activity in vitro or in 
vivo (Stammberger et al 2006). 
An analysis of safety data was compiled from the 
previously discussed trials for the purpose of FDA review 
(n = 1833 for insulin glulisine, n = 1524 for RHI or insulin 
lispro) (Gabry 2004). Overall, no signiﬁ  cant difference 
in the adverse event rate was noted with insulin glulisine 
versus the comparator insulins (66.2% vs 66.0% for type 1 
patients, 82.3% vs 79.6% for type 2 patients). The most com-
mon serious side-effect was severe hypoglycemia, the rate 
of which did not differ between treatments. The incidence 
of non-hypoglycemic adverse events was also comparable 
(12.8% vs 12.1%) with no differences in cardiac disorders, 
ketoacidosis, hypersensitivity, or injection site reactions. In 
total, 10 deaths (5 with insulin glulisine, 5 with comparator 
treatment) occurred throughout the clinical trials, none of 
which were attributed to the study treatment. In conclusion, 
compiled data on the safety of glulisine indicate that the 
analogue is as safe as human insulin.
Conclusion
All patients with type 1 DM and many patients with type 
2 DM require intensive insulin therapy to lower A1c to 
treatment goals and prevent long-term complications of the 
disease. When intensive insulin treatment is called for, a 
combination of long/intermediate and short acting insulins 
can be employed to provide both basal and bolus insulin 
needs. New insulin analogues, such as insulin glulisine, have 
been synthesized by recombinant DNA technology to provide 
more physiologic bolus insulin. Insulin glulisine, which has a 
two amino acid substitution of the B chain of human insulin, 
has a more rapid absorption and shorter duration of action 
than RHI exhibited across a wide range of patient subtypes 
(obese, renally impaired, different ethnic background, and 
pediatric clinical trials have demonstrated comparable or 
greater efﬁ  cacy of insulin glulisine versus insulin lispro or 
RHI, respectively). In addition, glulisine appears to have a 
more rapid time action proﬁ  le compared to insulin lispro 
across various BMIs. In patients with type 2 DM, insulin 
glulisine lowered A1c to a greater extent than RHI. The safety 
and tolerability proﬁ  le of insulin glulisine is also comparable 
to that of insulin lispro or RHI in type 1 or 2 DM and it has 
been shown to be as safe and effective as insulin aspart when 
used in CSII therapy. In summary, insulin glulisine provides 
a worthy option for use as prandial insulin in a basal/bolus 
intensive insulin regimen.
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